Natalizumab induced blood eosinophilia: A retrospective pharmacovigilance cohort study and review of the literature

AbstractObjective To describe frequency of natalizumab related eosinophilia and clinical symptoms eosinophilic disease in our monocentric cohort. Methods Comparison characteristics 115 treated 116 untreated RRMS patients review literature. Results 38% had eosinophilia, which occurred significantly more frequently compared to MS (3%, p-value<0.001). In symptomatic patients, mean eosinophil counts were higher than asymptomatic developed within one year. Discussion Eosinophilia is a side effect mostly asymptomatic. However, few develop year after start an as severe effect.